ADVERTISEMENT

Piramal Pharma Q4 Review: Operationally Inline; FY25 Ends On A Strong Note, Says Motilal Oswal —Maintains Buy

Motilal Oswal maintains 'Buy' rating on Piramal Pharma but cuts target price

<div class="paragraphs"><p>Piramal Pharma maintained its guidance of $1.2 billion revenue with a 25% Ebitda margin in the CDMO segment by FY30.</p><p> (Photo Source: Company website)</p></div>
Piramal Pharma maintained its guidance of $1.2 billion revenue with a 25% Ebitda margin in the CDMO segment by FY30.

(Photo Source: Company website)

Piramal Pharma delivered in-line sales/Ebitda in Q4 FY25. However, its earnings were below our estimate due to impairment of certain intangible assets during the quarter.
To continue reading this story
Subscribe to Unlock & Enjoy your 
Subscriber-Only
 benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit